Expert Opinion on Therapeutic Targets最新文献

DDR1 as a therapeutic target for neurological and psychiatric disorders. DDR1作为神经和精神疾病的治疗靶点。

IF 4.4 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2025-10-07 DOI: 10.1080/14728222.2025.2571056

Gemma Riesco, Elisabet Vilella

引用次数: 0

Unveiling the role of mineralocorticoid receptor antagonists in epilepsy: the intersection of seizures, stress, and neuroinflammation. 揭示矿皮质激素受体拮抗剂在癫痫中的作用：癫痫发作、应激和神经炎症的交集。

IF 4.4 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2025-10-06 DOI: 10.1080/14728222.2025.2571057

Deepanshu Goyal, Maanvi Dhureja, Puneet Kumar

{"title":"Unveiling the role of mineralocorticoid receptor antagonists in epilepsy: the intersection of seizures, stress, and neuroinflammation.","authors":"Deepanshu Goyal, Maanvi Dhureja, Puneet Kumar","doi":"10.1080/14728222.2025.2571057","DOIUrl":"10.1080/14728222.2025.2571057","url":null,"abstract":"Introduction: Epilepsy often presents numerous comorbidities, including anxiety, depression, and cognitive deficits. Epilepsy is not only restricted to GABA/glutamate imbalance, as researchers are delving more into finding the possible causal inference between other factors; one such recognized interplay is between seizures, stress, and inflammation. Stress-induced hypothalamic-pituitary-adrenal (HPA) axis activation increases corticosteroid release, which binds to mineralocorticoid receptors (MR), intensifies the release of neuroinflammatory markers, lowers seizure threshold, and worsens seizure susceptibility.Areas covered: Recent studies have demonstrated the potential advantages of MR antagonists in lowering seizure susceptibility. MR antagonists reestablish the equilibrium between MRs and GRs by inhibiting corticosteroid binding on MRs, thereby maintaining the balance between pro- and anti-inflammatory mediators. MR antagonists have been undergoing clinical trials as adjuvant therapy for management of psychological disorders by reducing neuroinflammation and altering body's reaction to stress. In addition to assessing the possible contribution of MR antagonists in the reduction of comorbidities linked to epilepsy, this review also elucidates mechanisms that underlie the connection between seizures, stress, and inflammation.Expert opinion: By addressing these gaps, future research can provide a more comprehensive understanding of MR signaling in epilepsy, ultimately leading to personalized treatment strategies and novel therapeutic targets.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"1-15"},"PeriodicalIF":4.4,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145228310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Identifying protease-activated targets and exploring therapeutic applications. 确定蛋白酶激活靶点并探索治疗应用。

IF 4.4 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2025-09-21 DOI: 10.1080/14728222.2025.2563244

Deokhee Kang, Charles S Craik

{"title":"Identifying protease-activated targets and exploring therapeutic applications.","authors":"Deokhee Kang, Charles S Craik","doi":"10.1080/14728222.2025.2563244","DOIUrl":"10.1080/14728222.2025.2563244","url":null,"abstract":"Introduction: Proteases are essential enzymes that regulate protein turnover and activate signaling pathways through targeted peptide bond cleavage. While traditionally regarded as degradative agents, proteases are now recognized for their diverse roles in health and disease, particularly in cancer and viral infections. Advances in high-throughput, mass spectrometry-based technologies have enabled proteome-wide identification of protease substrates, revealing numerous potential therapeutic targets. As large-scale approaches yield expansive substrate lists, it is increasingly important to understand the roles of disease-related proteases within their specific biological contexts.Areas covered: Peptide-level chemical libraries have provided more practical insights, facilitating the development of protease-targeted interventions. However, early efforts to derive inhibitors from these substrates faced challenges due to enzymatic redundancy and substrate promiscuity. Consequently, emerging research has shifted toward harnessing proteolytic activity for conditional activation of therapeutics. Since proteolytic activation can amplify therapeutic effects, protease-activated strategies, such as protease-cleavable linkers in antibody-drug conjugates, have gained interest and are now being applied to other therapeutic modalities.Expert opinion: We believe that identifying substrates activated by disease-associated proteases, enabled by recent technological advances, will lead to deeper biological insights. When combined with peptide-level techniques, these discoveries can drive the development of efficient therapeutic interventions with amplified effects.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"1-15"},"PeriodicalIF":4.4,"publicationDate":"2025-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145080075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The membrane receptor CD44: roles in neurodegenerative diseases. 膜受体CD44：在神经退行性疾病中的作用。

IF 4.4 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2025-09-21 DOI: 10.1080/14728222.2025.2563243

Meichen Zhang, Yongqi Lin, Huanhuan Wei, Qianqian Ju, Tong Gao, Yiyin Zhang, Lihua Shen, Cheng Sun

{"title":"The membrane receptor CD44: roles in neurodegenerative diseases.","authors":"Meichen Zhang, Yongqi Lin, Huanhuan Wei, Qianqian Ju, Tong Gao, Yiyin Zhang, Lihua Shen, Cheng Sun","doi":"10.1080/14728222.2025.2563243","DOIUrl":"10.1080/14728222.2025.2563243","url":null,"abstract":"Introduction: With the increasing prevalence of aging populations, the incidence of neurodegenerative diseases continues to rise, posing a serious threat to human health and quality of life. Owing to the highly complex pathogenesis of these disorders, the identification of effective therapeutic targets remains a major challenge. CD44, a cell surface glycoprotein, plays a central role in regulating cell proliferation, survival, adhesion, and migration. Emerging evidence further indicates that CD44 contributes to NF-κB activation, thereby amplifying inflammatory responses.Areas covered: Given its central role in neuroinflammation, CD44 has attracted increasing attention as a potential therapeutic target for neurodegenerative diseases. This review explores the involvement of CD44 in amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), and Parkinson's disease (PD), with particular emphasis on its contributions to neuroinflammatory processes, neuronal survival, and pathological protein aggregation.Expert opinion: Chronic low-grade neuroinflammation is a major driver of neurodegenerative diseases, including ALS, AD, and PD. Growing evidence implicates CD44 as a key contributor to disease pathogenesis, with several studies reporting significantly elevated CD44 expression in affected patients. These findings highlight the role of CD44 in disease progression and suggest that targeting CD44-mediated inflammation may offer a promising therapeutic strategy for neurodegenerative disorders.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"1-10"},"PeriodicalIF":4.4,"publicationDate":"2025-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145074845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Role of serotonin in the neurobiology of attention-deficit/hyperactivity disorder: a systematic literature review. 5 -羟色胺在注意缺陷/多动障碍的神经生物学中的作用：系统的文献综述。

IF 4.4 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2025-09-01 Epub Date: 2025-09-03 DOI: 10.1080/14728222.2025.2552324

Stephen V Faraone, Caroline L Ward, Matthieu Boucher, Reem Elbekai, Elizabeth Brunner

{"title":"Role of serotonin in the neurobiology of attention-deficit/hyperactivity disorder: a systematic literature review.","authors":"Stephen V Faraone, Caroline L Ward, Matthieu Boucher, Reem Elbekai, Elizabeth Brunner","doi":"10.1080/14728222.2025.2552324","DOIUrl":"10.1080/14728222.2025.2552324","url":null,"abstract":"Introduction: Attention-deficit/hyperactivity disorder (ADHD) is a common neuropsychiatric disorder of inattention, hyperactivity, and impulsivity. Roles for dopamine and norepinephrine are widely recognized; however, the role of serotonergic neurotransmission is less clear. This systematic literature review aimed to determine if changes in serotonin transmission are implicated in the neurobiology of ADHD.Methods: A search of published literature was conducted. Eligible publications addressing the role of serotonin, its receptor family, and/or its transporter in the neurobiology of ADHD were selected according to prespecified criteria. The quality of evidence was graded.Results: Of 95 publications meeting our criteria, many (n = 60) were nonclinical studies. Most publications were rated as containing medium- (62.1%) or high-grade (17.9%) evidence. Multiple strands of evidence were found to implicate serotonin in ADHD, with 81.1% of the identified articles providing support for altered levels of serotonin production, binding, transport, or degradation in ADHD.Conclusions: Substantial evidence implicates serotonin in the neurobiology of ADHD and in the regulation of the catecholaminergic systems believed to be dysregulated by the disorder. Yet this evidence is incomplete and, at times, conflicting. It does suggest, however, that medications that engage the serotonin system should be tested for their efficacy in the treatment of ADHD.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"637-654"},"PeriodicalIF":4.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144948164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Precision targeting of the melanocortin-1 receptor with radiopharmaceuticals in metastatic melanoma. 放射性药物在转移性黑色素瘤中精确靶向黑色素皮质素-1受体。

IF 4.4 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2025-09-01 Epub Date: 2025-09-09 DOI: 10.1080/14728222.2025.2557277

Hiroyuki Suzuki, Tomoya Uehara

引用次数: 0

Targeting activin E: insights in to role in adipose tissue and prospects for weight loss therapeutic development. 靶向激活E：在脂肪组织中的作用及减肥治疗发展的前景。

IF 4.4 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2025-09-01 Epub Date: 2025-09-09 DOI: 10.1080/14728222.2025.2558185

Osamu Hashimoto, Maho Sakaki

引用次数: 0

The potential of thromboxane A₂ as a therapeutic target: prospects and challenges. 血栓素A₂作为治疗靶点的潜力：前景和挑战。

IF 4.4 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2025-09-01 Epub Date: 2025-09-06 DOI: 10.1080/14728222.2025.2557282

Ralf A Benndorf

引用次数: 0

The contribution of fibronectin in epileptogenesis: therapeutic potential and mechanistic complexity. 纤维连接蛋白在癫痫发生中的作用：治疗潜力和机制复杂性。

IF 4.4 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2025-09-01 Epub Date: 2025-09-08 DOI: 10.1080/14728222.2025.2557276

Neha Dixit, Nitin Yadav, Priya, Jyotirmoy Banerjee, Manjari Tripathi, P Sarat Chandra, Aparna Banerjee Dixit

{"title":"The contribution of fibronectin in epileptogenesis: therapeutic potential and mechanistic complexity.","authors":"Neha Dixit, Nitin Yadav, Priya, Jyotirmoy Banerjee, Manjari Tripathi, P Sarat Chandra, Aparna Banerjee Dixit","doi":"10.1080/14728222.2025.2557276","DOIUrl":"10.1080/14728222.2025.2557276","url":null,"abstract":"Introduction: Epilepsy is a chronic neurological disorder leading to repeateduncontrollable seizures. The available armamentarium of ~ 30 antiseizure drugsis unable to control seizures in a third of the patients, which signifies the need to look for novel therapeutic targets with alternative mechanisms of action.Areas covered: Fibronectin, an extracellular matrix (ECM) glycoprotein,is involved in epileptogenesis as shown by several clinical and preclinicalstudies. There is ample evidence supporting fibronectin's role in modulatingkey pathognomonic events during epileptogenesis. This review presents a conciseoverview of fibronectin's contribution to the initiation and progression ofepilepsy. Additionally, we highlight the potential of fibronectin to betargeted for developing novel anti-epileptogenic therapeutics.Expert opinion: Epileptogenesis involves aberrant angiogenesis,blood-brain barrier (BBB) perturbation, neuroinflammation, synaptic remodeling,and neuronal hyperexcitability, all of which are significantly regulated byfibronectin. Small-molecule inhibitors against fibronectin could disrupt the signaling pathways that influence hyperexcitability, BBB disruption, andaberrant neurogenesis during epileptogenesis. Alternatively, delivering fibronectin/nanomedicine complex to the brain could help target neuroinflammation, as demonstrated in other diseases. However, current evidence supporting fibronectin as a therapeutic target in epilepsy remains limited,highlighting the need for further research to better understand its role in epileptogenesis.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"621-635"},"PeriodicalIF":4.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145000070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Disrupting Siglec-mediated interactions to develop immunotherapies for cancer treatment. 破坏siglecl介导的相互作用以开发用于癌症治疗的免疫疗法。

IF 4.4 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2025-09-01 Epub Date: 2025-09-09 DOI: 10.1080/14728222.2025.2557281

Heinz Läubli, Ajit Varki

{"title":"Disrupting Siglec-mediated interactions to develop immunotherapies for cancer treatment.","authors":"Heinz Läubli, Ajit Varki","doi":"10.1080/14728222.2025.2557281","DOIUrl":"10.1080/14728222.2025.2557281","url":null,"abstract":"Introduction: Recent advances in cancer immunotherapy have improved patient outcomes, even in advanced stages of the disease. However, the effectiveness of current cancer immunotherapies remains limited to a small subset of patients because of resistance and an immunosuppressive tumor microenvironment.Areas covered: Research performed during the last years have identified immunosuppressive interactions between sialic acid-containing glycans and sialic acid-binding immunoglobulin-like lectin (Siglec) receptors as a potential new, targetable pathway to overcome resistance to immunotherapy. In addition, activatory Siglecs could be engaged to enhance anti-tumor immunity. In this review, we summarize accumulating preclinical evidence demonstrating the immunosuppressive role of sialoglycan-Siglec interactions in cancer. Additionally, we provide an overview of potential therapeutic strategies aimed at disrupting this immunosuppressive axis, including interventions currently being evaluated in early-phase clinical trials.Expert opinion: Preclinical data strongly suggests that disrupting sialic acid-Siglec interactions could significantly improve cancer immunotherapy, in particular by changing the immunosuppressive microenvironment. Further biological understanding is needed to successfully develop new therapeutics. First trials are running that target these interactions and will hopefully inform, which patients are benefitting from this treatment.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"613-619"},"PeriodicalIF":4.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144947986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0